Showing 3971-3980 of 9150 results for "".
- EWG Surveys Personal Care Product Companies About Removing 1,4-Dioxanehttps://practicaldermatology.com/news/ewg-surveys-personal-care-product-companies-about-removing-14-dioxane/2458220/The Environmental Working Group (EWG) is surveying U.S. makers of personal care products to ask if they are working to remove 1,4-dioxane, a potential human carcinogen, from their products. At least 8,000 products on the market contain ethoxylated ingredie
- Chris Payne Named Chief Marketing Officer at PCA Skinhttps://practicaldermatology.com/news/chris-payne-named-chief-marketing-officer-at-pca-skin/2458454/Chris Payne has been named Chief Marketing Officer at Scottsdale, AZ-based PCA Skin. In this role, Payne will be responsible for leading all marketing and communication initiatives to drive growth of PCA SKIN through both professional and consum
- Men, New Technologies Drive Growth in Body Contouring Markethttps://practicaldermatology.com/news/men-new-technologies-drive-growth-in-body-contouring-market/2458467/The body contouring market is set to rise from $671.8 million in 2015 to more than $1.1 billion by 2022, representing a compound annual growth rate of 7.9%, according to research and consulting firm
- Pfizer/Anacor Merger To Fuel Already Robust AD Pipelinehttps://practicaldermatology.com/news/pfizeranacor-merger-fuels-already-robust-ad-pipeline/2458542/For years, there were few, if any, promising new treatments for atopic dermatitis (AD), but today the pipeline is robust, and a Pfizer-Anacor merger may help both of the companies’ pipeline candidates gain market share,
- FDA Approves Juvéderm Volbella XC for Use in Lips and Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-juvderm-volbella-xc-for-use-in-lips-and-perioral-rhytids/2458546/Allergan plc, has received FDA approval to market Juvéderm Volbella XC for use in the lips for lip augmentation and for correction of perioral rhytids, commonly referred to as perioral lines, in adults over the age of 21. In clinical trials, Juvéderm Volbella XC was found to effecti
- Global Derm Market Set to Soar Through 2022https://practicaldermatology.com/news/global-derm-market-set-to-soar-through-2022/2458579/The global dermatology market is set to boom from $20 billion in 2015 to $33.7 billion by 2022, representing a compound annual growth rate of 7.7%,
- Psoriasis Market Poised for Growth Spurt by 2024https://practicaldermatology.com/news/psoriasis-market-poised-for-growth-spurt-by-2024/2458609/The psoriasis market will more than double to $13.3 billion by 2024 as drugs greatly improve, according to a
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- Alastin SkinCare Appoints Lynn Salo to Board of Directorshttps://practicaldermatology.com/news/alastin-skincare-appoints-linda-salo-to-board-of-directors/2458719/Lynn Salo is now a member of ALASTIN™ Skincare, Inc.’s board of directors. Ms. Salo has 27 years of experience with Allergan in the U.S., Canada, and Europe, including her role as Vice President, Sales and Marketing for the Facial Aesthetic
- Study: MD Complete Holds Its Own Against Two Rx Skincare Regimenshttps://practicaldermatology.com/news/md-complete-holds-own-against-two-rx-skincare-regimens/2458736/A new split-face study suggests that a mass marketed skin care system can hold its own against two prescription skin care regimens when it comes to improving photoaged skin. The new findings, which compared MD Complete with two professi